我院重组人促红细胞生成素合理性应用评价分析  

Analysis of the application of recombinant human erythropoietin in our hospital

作　　者：王雪[1] 孙敏[1] 李静[1] 司继刚[1] WANG Xue;SUN Min;LI Jing;SI Ji-gang(Department of Pharmacy,Zibo Center Hospital,Zibo 255036,China)

机构地区：[1]淄博市中心医院药学部,山东淄博255036

出　　处：《中国药物应用与监测》2020年第2期108-112,共5页Chinese Journal of Drug Application and Monitoring

摘　　要：目的:了解我院重组人促红细胞生成素(rhEPO)的使用情况,为临床合理用药提供参考。方法:采用回顾性的分析方法,收集我院2019年7–12月使用rhEPO的住院患者信息,共计428例,对患者使用rhEPO的适应证、用法用量、治疗前后血红蛋白水平、合并用药和不良反应等进行统计分析。结果:428例患者中肾性贫血202例(47.20%)、肿瘤化疗引起的贫血132例(30.84%)和外科围手术期的红细胞动员23例(5.37%),合并使用铁剂的194例(45.33%)。存在的主要问题有适应证不适宜、用药时机不适宜和未根据治疗后血红蛋白水平调整剂量等。结论:rhEPO在我院的应用仍存在一定问题,需要进一步规范用药,确保患者用药安全有效。Objective:To review the use of recombinant human erythropoietin(rhEPO)in our hospital,and provide references for clinical rational drug use.Methods:Data of 428 inpatients using rhEPO from July to December in 2019 were retrospectively extracted from hospital information system and analyzed in terms of indications,usage and dosage,hemoglobin levels before and after treatment,combined medication,and adverse drug reaction.Results:Among the 428 patients,202 patients(47.20%)used rhEPO for renal anemia,132 patients(30.84%)used it for anemia caused by chemotherapy,and 23 patients(5.37%)used it for red blood cell mobilization in the period of peri-operation.194 cases(45.33%)used rhEPO combined with chalybeate.The main problems of irrational use of rhEPO were inappropriate indication,inappropriate timing of administration,no dose adjustment based on post-treatment hemoglobin levels and so on.Conclusion:There were still some problems in the application of rhEPO in our hospital.It was necessary to further standardize the medication to ensure the safety and effectiveness of drug use.

关 键 词：重组人促红细胞生成素 用药分析 住院医嘱 

分 类 号：R969.3[医药卫生—药理学] R973[医药卫生—药学]